Citadel Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-12,900
| Closed | -$62K | – | 10888 |
|
|
2020
Q1 | $62K | Buy |
12,900
+500
| +4% | +$3.24K | ﹤0.01% | 8927 |
|
|
2019
Q4 | $132K | Buy |
+12,400
| New | +$123K | ﹤0.01% | 8427 |
|
|
2019
Q2 | – | Sell |
-16,800
| Closed | -$216K | – | 10205 |
|
|
2019
Q1 | $216K | Sell |
16,800
-3,500
| -17% | -$39.6K | ﹤0.01% | 8109 |
|
|
2018
Q4 | $193K | Buy |
20,300
+4,700
| +30% | +$60.9K | ﹤0.01% | 7895 |
|
|
2018
Q3 | $259K | Buy |
15,600
+1,500
| +11% | +$24.1K | ﹤0.01% | 7823 |
|
|
2018
Q2 | $226K | Buy |
+14,100
| New | +$252K | ﹤0.01% | 7680 |
|
|
2015
Q3 | – | Sell |
-4,500
| Closed | -$53K | – | 9413 |
|
|
2015
Q2 | $53K | Sell |
4,500
-2,600
| -37% | -$36.1K | ﹤0.01% | 7620 |
|
|
2015
Q1 | $103K | Buy |
7,100
+6,700
| +1,675% | +$103K | ﹤0.01% | 6824 |
|
|
2014
Q4 | $7K | Sell |
400
-3,200
| -89% | -$46.1K | ﹤0.01% | 8216 |
|
|
2014
Q3 | $45K | Buy |
+3,600
| New | +$44.3K | ﹤0.01% | 6968 |
|
Citadel Advisors's STML Position: Q2 2020 in Review
Citadel Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 88,520 shares — an estimated $429K sold.
Citadel Advisors first reported a position in STML in Q3 2013 and held it in 15 quarters. The position peaked at $15M in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Citadel Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Citadel Advisors sold 88,520 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $429K.
- Citadel Advisors first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 15 quarters.
- Citadel Advisors's Stemline Therapeutics, Inc. position peaked at $15M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.